[go: up one dir, main page]

IS5712A - Faststilling lyfjablandna sem í eru angíótensínumbreytiensím með magnesíumoxíði - Google Patents

Faststilling lyfjablandna sem í eru angíótensínumbreytiensím með magnesíumoxíði

Info

Publication number
IS5712A
IS5712A IS5712A IS5712A IS5712A IS 5712 A IS5712 A IS 5712A IS 5712 A IS5712 A IS 5712A IS 5712 A IS5712 A IS 5712A IS 5712 A IS5712 A IS 5712A
Authority
IS
Iceland
Prior art keywords
determination
pharmaceutical compositions
magnesium oxide
compositions containing
converting enzyme
Prior art date
Application number
IS5712A
Other languages
English (en)
Other versions
IS2270B (is
Inventor
Ellen Daniel Jane
Ray Harris Michael
Original Assignee
Warner - Lambert Company, , Delaware Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22210458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5712(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner - Lambert Company, , Delaware Corporation filed Critical Warner - Lambert Company, , Delaware Corporation
Publication of IS5712A publication Critical patent/IS5712A/is
Publication of IS2270B publication Critical patent/IS2270B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08Oxides; Hydroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2068Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS5712A 1998-06-05 2000-11-10 Faststilling lyfjablandna sem í eru angíótensínumbreytiensím með magnesíumoxíði IS2270B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8828098P 1998-06-05 1998-06-05
PCT/US1999/010189 WO1999062560A1 (en) 1998-06-05 1999-05-10 Stabilization of compositions containing ace inhibitors using magnesium oxide

Publications (2)

Publication Number Publication Date
IS5712A true IS5712A (is) 2000-11-10
IS2270B IS2270B (is) 2007-07-15

Family

ID=22210458

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5712A IS2270B (is) 1998-06-05 2000-11-10 Faststilling lyfjablandna sem í eru angíótensínumbreytiensím með magnesíumoxíði

Country Status (32)

Country Link
US (3) US6417196B1 (is)
EP (1) EP1083931B1 (is)
JP (1) JP3727848B2 (is)
KR (1) KR20010052557A (is)
CN (1) CN1144598C (is)
AR (1) AR019150A1 (is)
AT (1) ATE295184T1 (is)
AU (1) AU755616B2 (is)
BR (1) BR9910947A (is)
CA (1) CA2330581A1 (is)
CO (1) CO5011043A1 (is)
DE (1) DE69925269T2 (is)
ES (1) ES2242398T3 (is)
GT (1) GT199900079A (is)
HK (1) HK1038879B (is)
HN (1) HN1999000088A (is)
HU (1) HUP0102260A3 (is)
ID (1) ID27398A (is)
IL (1) IL139590A0 (is)
IS (1) IS2270B (is)
MY (1) MY119667A (is)
NO (1) NO20006148L (is)
NZ (1) NZ508544A (is)
PA (1) PA8475001A1 (is)
PE (1) PE20000543A1 (is)
PL (1) PL344586A1 (is)
SV (1) SV1999000072A (is)
TR (1) TR200003600T2 (is)
TW (1) TW565455B (is)
UY (1) UY25546A1 (is)
WO (1) WO1999062560A1 (is)
ZA (1) ZA200006537B (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69925269T2 (de) * 1998-06-05 2006-02-23 Warner-Lambert Co. Llc Stabilisierung von zusammensetzungen enthaltend ace-hemmer durch magnesiumoxid
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
EP1300160B1 (en) * 2000-05-24 2014-03-12 Otsuka Pharmaceutical Co., Ltd. Method of stabilizing preparation
EA007981B1 (ru) * 2002-01-15 2007-02-27 Актавис Груп Хф. Фармацевтический состав, содержащий хинаприл или фармацевтически приемлемую его соль
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
WO2004073729A1 (ja) * 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
CA2519287A1 (en) 2003-03-27 2004-10-14 Bioactis Limited Powder medicine applicator for nasal cavity
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
PT1635792E (pt) * 2003-06-26 2009-05-15 Teva Pharma Composições farmacêuticas estáveis de derivados do ácido 2-aza-biciclo[3.3.0]octano-3-carboxílico
JP4922762B2 (ja) * 2004-08-10 2012-04-25 株式会社新日本科学 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
ITMI20060026A1 (it) * 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
US20080015188A1 (en) * 2006-04-19 2008-01-17 Julia Hrakovsky Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives
WO2008000040A1 (en) * 2006-06-30 2008-01-03 Alphapharm Pty Ltd A stabilised composition comprising ace inhibitors
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CN102512656B (zh) * 2011-12-27 2013-11-27 天津市嵩锐医药科技有限公司 盐酸喹那普利药物组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320029A (en) * 1967-05-16 Method of preparing magnesia
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4425355A (en) * 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4793998A (en) * 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4830583A (en) * 1988-03-02 1989-05-16 Sri International Fluid motor-pumping apparatus and system
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
DE69925269T2 (de) * 1998-06-05 2006-02-23 Warner-Lambert Co. Llc Stabilisierung von zusammensetzungen enthaltend ace-hemmer durch magnesiumoxid
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor

Also Published As

Publication number Publication date
EP1083931A1 (en) 2001-03-21
HK1038879A1 (en) 2002-04-04
IL139590A0 (en) 2002-02-10
JP2002516881A (ja) 2002-06-11
DE69925269D1 (de) 2005-06-16
CO5011043A1 (es) 2001-02-28
HUP0102260A2 (hu) 2002-03-28
SV1999000072A (es) 2000-05-04
EP1083931B1 (en) 2005-05-11
HK1038879B (zh) 2004-10-08
AU3979399A (en) 1999-12-20
TW565455B (en) 2003-12-11
ATE295184T1 (de) 2005-05-15
ES2242398T3 (es) 2005-11-01
AR019150A1 (es) 2001-12-26
HN1999000088A (es) 2000-02-10
US7015232B2 (en) 2006-03-21
NZ508544A (en) 2002-10-25
GT199900079A (es) 2000-11-25
DE69925269T2 (de) 2006-02-23
HUP0102260A3 (en) 2002-12-28
CN1144598C (zh) 2004-04-07
PE20000543A1 (es) 2000-08-10
NO20006148D0 (no) 2000-12-04
PA8475001A1 (es) 2000-09-29
CA2330581A1 (en) 1999-12-09
CN1304322A (zh) 2001-07-18
ID27398A (id) 2001-04-05
PL344586A1 (en) 2001-11-05
AU755616B2 (en) 2002-12-19
WO1999062560A1 (en) 1999-12-09
US20020161020A1 (en) 2002-10-31
IS2270B (is) 2007-07-15
TR200003600T2 (tr) 2001-04-20
BR9910947A (pt) 2001-03-06
ZA200006537B (en) 2001-11-12
UY25546A1 (es) 1999-09-27
JP3727848B2 (ja) 2005-12-21
NO20006148L (no) 2000-12-04
US20060106057A1 (en) 2006-05-18
MY119667A (en) 2005-06-30
US6417196B1 (en) 2002-07-09
KR20010052557A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
IS5712A (is) Faststilling lyfjablandna sem í eru angíótensínumbreytiensím með magnesíumoxíði
AU2002239262A1 (en) Compositions of peptide crystals
EP1033624A4 (en) CHEMICALLY REINFORCED RESIST COMPOSITION
AU5982999A (en) Antiperspirant compositions
AU7620200A (en) Compositions and methods relating to the inhibition of casomorphin and gluteomorphin
PT1014987E (pt) Composicoes orais de levosimendano
ATE360374T1 (de) Feste zusammensetzungen zur verminderung der zahnerosion
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
AU2001238718A1 (en) Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
AU1769400A (en) Gas detection according to the principle of measuring work functions
EP1069895A4 (en) COMPOSITIONS CONTAINING LYSOPHOSPHATIDE ACIDS THAT INHIBIT APOPTOSIS AND USES THEREOF
AU2003287063A8 (en) Hemostatic and acid etch compositions containing sucralose
DE19981910T1 (de) Gasbildende Zusammensetzung
AU2003272896A1 (en) Valerolactone compounds and perfume composition
AU2003217916A1 (en) Stable formulations of angiotensin converting enzyme (ace) inhibitors
NO20011664D0 (no) Sammensetning med höy renhet omfattende (7<alfa>, 17<alfa>)- 17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on
AU2003241103A8 (en) Compositions containing anti-hiv peptides and methods of use
PL342165A1 (en) Antienzymic composition containing ethylenediamino disuscinic acid
DE60015250D1 (de) Versiegelungszusammensetzung
AU5507999A (en) Monocyclic compounds having nk-2 antagonist action and compositions containing them
TW370915U (en) Structure of wrench
SE0203367L (sv) Elektrisk anslutning till keramisk förseglingsback samt sätt att åstadkomma nämnda anslutning
AU5254499A (en) Ozone destroying compositions of improved tolerance to sulfur poisoning
AU2003206589A1 (en) Antihypertensive compositions and uses thereof
RU2002117869A (ru) Тампонажный состав для изоляции проницаемых пластов